MEDVidi vs He & She MD
An in-depth comparison of two leading GLP-1 Providers
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
He & She MD
Best for: starting below a standard dose, with microdose tiers
Visit He & She MD →Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, He & She MD starts at $99/mo, and He & She MD finishes ahead, 9.3 to 4.4. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.
Pricing
MEDVidi
Pricing not publicly listed.
He & She MD
⛔ THIS ROW PREVIOUSLY DESCRIBED A "microdose" TIER THAT DOES NOT EXIST. Read live from heandshemd.com/weight-loss on 2026-08-14: the word "microdose" appears NOWHERE on the homepage or the weight-loss page. $99 is Semaglutide Injection, and its own asterisk reads "Price for purchase of 12 months supply" — a twelve-month prepay divided down, which is the LONGEST commitment the clinic sells, not the shortest. The figure was real; the product was invented. The standing month-to-month rate for injectable semaglutide is $199.
Injectable tirzepatide intro $199/mo (regular $289/mo)
What’s included
MEDVidi
Covered by the monthly price
Medication
Charged on top
Clinician visits
In the price
Shipping
Charged on top
Lab work
Not stated
Coaching
Not stated
He & She MD
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
In the price
Score breakdown
Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.
MEDVidi
4.4/10
He & She MD
9.3/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
Features & Coverage
| Feature | MEDVidi | He & She MD |
|---|---|---|
| Starting Price | — | $99/mo |
| Features | 6 features | ✓8 features |
| States Available | Not disclosed | 50 |
| Compounded | — | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
About MEDVidi
Each visit carries its own charge instead of a bundled subscription: 195 dollars to start, 159 dollars for a follow-up. Because the prescription travels to whichever pharmacy the patient picks, the drug is billed apart. Providers holding licenses evaluate patients and write phentermine, Qsymia and Saxenda alongside the brand-name Wegovy (semaglutide) and Zepbound (tirzepatide). The footprint is 33 states. Do not confuse the brand with MEDVi (medvi.com), which is a different one.
Read our full MEDVidi review →About He & She MD
GLP-1 Platinum opens at $139/month as an introductory rate on injectables, then settles at $199. That buys expedited delivery at no cost, board-certified clinicians reachable without limit, GLP-1 coaching and progress tracking inside the app, and billing only happens if a prescription is actually written. He & She MD works nationwide with doctor-prescribed compounded semaglutide and tirzepatide, injectable or oral, a microdose option, and access under brand names to Wegovy, Ozempic and Zepbound. Every state receives shipments except Louisiana. Certification is LegitScript.
Read our full He & She MD review →Pros & Cons
MEDVidi
What we like
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers consult
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- Billed separately from the monthly figure: medication, shipping
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
He & She MD
What we like
- Semaglutide at $99 a month, 48% below the $189 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers medication, consult, shipping, coaching
- Coverage is published for all 50 states
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
He & She MD takes it, 9.3 against 4.4, and it is especially strong on starting below a standard dose, with microdose tiers. MEDVidi is no weak second.
Choose He & She MD if…
You want starting below a standard dose, with microdose tiers and an opening price near $99 a month.
Ready to start? Vetted GLP-1 providers
Vetted telehealth providers that prescribe GLP-1 online.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Strut Health
Semaglutide at $99/month, 48% under the register median
From $99/mo
Get started →Oak
Semaglutide at $119/month, 37% under the register median
From $119/mo
Get started →Found
Tirzepatide at $169/month, 37% under the register median
From $99/mo
Get started →MEDVidi vs He & She MD: FAQ
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring MEDVidi and He & She MD head-to-heads in the same category.
- MEDVidi vs Trimi Health
- MEDVidi vs Embody
- MEDVidi vs Lean Meds
- He & She MD vs NextMeds
- He & She MD vs bmiMD
- He & She MD vs CoreAge Rx
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.